Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 5
2003 2
2004 1
2005 1
2006 3
2007 4
2008 4
2009 5
2010 3
2011 4
2012 6
2013 3
2014 2
2015 2
2016 5
2017 2
2018 4
2019 7
2020 10
2021 15
2022 17
2023 12
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

99 results

Results by year

Filters applied: . Clear all
Page 1
Neoadjuvant Chemoradiotherapy Followed by Radical Cystectomy for Muscle-Invasive Bladder Cancer: Analysis of Efficacy and Safety in 119 Patients.
Fujiwara M, Tanaka H, Kobayashi M, Nakamura Y, Fan B, Ishikawa Y, Fukuda S, Toda K, Yoshida S, Yokoyama M, Yoshimura R, Fujii Y. Fujiwara M, et al. Among authors: yoshimura r. Clin Genitourin Cancer. 2024 Apr;22(2):193-200.e1. doi: 10.1016/j.clgc.2023.10.013. Epub 2023 Nov 2. Clin Genitourin Cancer. 2024. PMID: 38000954
Feasibility of accelerated partial breast irradiation with strut-adjusted volume implant brachytherapy in Japan focusing on dosimetry and acute toxicity: a Japanese multi-institutional prospective study.
Yoshida M, Yoshimura RI, Notake R, Shinjo H, Miyaura K, Kuwayama T, Kawanaka T, Shien T, Yoshio K, Shiga T, Kaneyasu Y, Nakagawa T, Kubota K, Nakamura S, Itami J; Working group of APBI with SAVIs in Japan (WASAVIs). Yoshida M, et al. Breast Cancer. 2024 Jan;31(1):75-83. doi: 10.1007/s12282-023-01513-x. Epub 2023 Oct 21. Breast Cancer. 2024. PMID: 37865624
A phase II randomized trial of metastasis-directed therapy with alpha emitter radium-223 in men with oligometastatic castration-resistant prostate cancer (MEDAL).
Yoshida S, Takahara T, Arita Y, Ito M, Hayakawa S, Oguchi T, Komai Y, Numao N, Yuasa T, Inoue M, Ushijima H, Kudo S, Shimano Y, Nakamura Y, Uchida Y, Uehara S, Tanaka H, Yaegashi H, Izumi K, Yokoyama M, Matsuoka Y, Yoshioka Y, Konishi K, Nakanishi K, Nagahara A, Hirakawa A, Koike R, Koga F, Nishimura K, Mizokami A, Yonese J, Kageyama Y, Yoshimura R, Fujii Y. Yoshida S, et al. Among authors: yoshimura r. BMC Urol. 2023 Mar 6;23(1):33. doi: 10.1186/s12894-023-01202-z. BMC Urol. 2023. PMID: 36879257 Free PMC article. Clinical Trial.
99 results